Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2019 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Results by year

Filters applied: . Clear all
Page 1
Pre-therapeutic evaluation and practical management of cardiovascular and renal toxicities in patients with metastatic radioiodine-refractory thyroid cancer treated with lenvatinib.
Wassermann J, Bagnis CI, Leenhardt L, Ederhy S, Buffet C. Wassermann J, et al. Expert Opin Drug Saf. 2022 Nov;21(11):1401-1410. doi: 10.1080/14740338.2022.2153115. Epub 2022 Dec 7. Expert Opin Drug Saf. 2022. PMID: 36458701 Review.
Although patients treated with lenvatinib have been shown to have a significant improvement in progression-free survival, lenvatinib-associated toxicity may result in dose reductions, dose interruptions or even complete lenvatinib withdrawal, compromising ant …
Although patients treated with lenvatinib have been shown to have a significant improvement in progression-free survival, lenvatin …
Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit.
Shah RR, Morganroth J. Shah RR, et al. Drug Saf. 2015 Aug;38(8):693-710. doi: 10.1007/s40264-015-0300-1. Drug Saf. 2015. PMID: 26008987 Review.
This report is an update on the cardiovascular safety of those 16 TKIs, including the post-marketing data concerning their pro-arrhythmic effects, and reviews the cardiovascular safety of the nine new TKIs approved since (afatinib, cabozantinib, ceritinib, dabrafenib, ibrutinib, …
This report is an update on the cardiovascular safety of those 16 TKIs, including the post-marketing data concerning their pro-arrhythmic ef …
Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea.
Kim SY, Kim SM, Chang H, Kim BW, Lee YS, Chang HS, Park CS. Kim SY, et al. Front Endocrinol (Lausanne). 2019 Jun 12;10:384. doi: 10.3389/fendo.2019.00384. eCollection 2019. Front Endocrinol (Lausanne). 2019. PMID: 31244783 Free PMC article.
Four (17.4%) lenvatinib-treated patients and 26 (54.2%) sorafenib-treated patients required treatment discontinuation. ...The incidence of hand-foot skin reaction, alopecia, and rash of any grade was significantly lower (P = 0.003, P = 0.017, and P = 0.017) in patients tre …
Four (17.4%) lenvatinib-treated patients and 26 (54.2%) sorafenib-treated patients required treatment discontinuation. ...The inciden …
Effect of lenvatinib (E7080) on the QTc interval: results from a thorough QT study in healthy volunteers.
Shumaker RC, Zhou M, Ren M, Fan J, Martinez G, Aluri J, Darpo B. Shumaker RC, et al. Cancer Chemother Pharmacol. 2014 Jun;73(6):1109-17. doi: 10.1007/s00280-014-2444-6. Cancer Chemother Pharmacol. 2014. PMID: 24658627 Clinical Trial.
Lenvatinib is not genotoxic, therefore, this thorough QT (TQT)study with lenvatinib, a multityrosine kinase inhibitor, was undertaken utilizing healthy volunteers and concentration effect modeling to project the TQT effect at high plasma levels. ...The safety …
Lenvatinib is not genotoxic, therefore, this thorough QT (TQT)study with lenvatinib, a multityrosine kinase inhibitor, …